GILEAD SCIENCES SL
- Country
- 🇪🇸Spain
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2011-11-24
- Last Posted Date
- 2019-04-17
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 266
- Registration Number
- NCT01479465
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸West Michigan Cancer Center, Kalamazoo, Michigan, United States
🇺🇸Providence Saint Joseph Medical Center-Disney Family Cancer Center, Burbank, California, United States
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
- Conditions
- Interventions
- First Posted Date
- 2011-11-21
- Last Posted Date
- 2016-06-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 438
- Registration Number
- NCT01475838
- Locations
- 🇺🇸
Peter J. Ruane, M.D., Inc., Los Angeles, California, United States
🇺🇸OASIS Clinic, Los Angeles, California, United States
🇺🇸Gordon Crofoot Md, Pa, Houston, Texas, United States
Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2011-11-16
- Last Posted Date
- 2014-10-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 465
- Registration Number
- NCT01472185
- Locations
- 🇺🇸
Thunderbird Internal Medicine/Clinical Research Advantage, Glendale, Arizona, United States
🇺🇸North Central Arkansas Medical Associates, Mountain Home, Arkansas, United States
🇺🇸Desert Sun Clinical Research, LLC, Tucson, Arizona, United States
A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2011-11-16
- Last Posted Date
- 2015-03-10
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 250
- Registration Number
- NCT01472198
- Locations
- 🇺🇸
UCLA Community Oncology Practice, Los Angeles, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States
Gilead Sustained Virologic Response (SVR) Registry
- Conditions
- First Posted Date
- 2011-10-24
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 6625
- Registration Number
- NCT01457755
- Locations
- 🇺🇸
University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States
🇺🇸Methodist Dallas Medical Center, Dallas, Texas, United States
🇺🇸Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
- Conditions
- First Posted Date
- 2011-10-24
- Last Posted Date
- 2018-05-04
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 570
- Registration Number
- NCT01457768
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Medical College of Wisconsin, Chicago, Illinois, United States
Pilot Study of Simtuzumab in the Treatment of Liver Fibrosis
- First Posted Date
- 2011-10-14
- Last Posted Date
- 2014-02-03
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 20
- Registration Number
- NCT01452308
- Locations
- 🇺🇸
Weill Cornell Medical College: NewYork-Presbyterian Hospital, New York, New York, United States
Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)
- Conditions
- Interventions
- First Posted Date
- 2011-09-28
- Last Posted Date
- 2016-07-15
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 2651
- Registration Number
- NCT01442038
- Locations
- 🇺🇸
Tallahassee Research Institute, Tallahassee, Florida, United States
🇺🇸Union Memorial Hospital, Baltimore, Maryland, United States
🇺🇸Veterans Administration Medical Center, Pittsburgh, Pennsylvania, United States
Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
- Conditions
- Interventions
- First Posted Date
- 2011-09-26
- Last Posted Date
- 2016-12-14
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 314
- Registration Number
- NCT01440569
- Locations
- 🇺🇸
Gary J. Richmond,M.D., P.A., Fort Lauderdale, Florida, United States
🇺🇸Atlanta ID group, Atlanta, Georgia, United States
🇺🇸Mercer University, Macon, Georgia, United States
GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection
- Conditions
- Interventions
- First Posted Date
- 2011-09-16
- Last Posted Date
- 2013-12-17
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 170
- Registration Number
- NCT01435226
- Locations
- 🇺🇸
Advanced Clinical Research Institute, LLC, Anaheim, California, United States
🇺🇸Lightsource Medical, Los Angeles, California, United States
🇺🇸Medical Associates Research Group, Inc., San Diego, California, United States